Cigna Corporation (CGN.F)
| Previous close | 331.20 |
| Open | 332.00 |
| Bid | 337.90 x 20000 |
| Ask | 340.00 x 20000 |
| Day's range | 332.00 - 332.00 |
| 52-week range | 219.70 - 337.20 |
| Volume | |
| Avg. volume | 15 |
| Market cap | 95.215B |
| Beta (5Y monthly) | 0.58 |
| PE ratio (TTM) | 20.46 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 5.23 (1.58%) |
| Ex-dividend date | 04 Jun 2024 |
| 1y target est | N/A |
- PR Newswire
The Cigna Group Reports Strong First Quarter 2024 Results, Raises 2024 Outlook
Global health company The Cigna Group (NYSE: CI) today reported strong first quarter 2024 results reflecting growth across its diversified portfolio of businesses.
- PR Newswire
New Report: Employers Play Critical Role in Curbing Today's Youth Mental Health Crisis
Many American children struggling with mental health challenges do not receive optimal care, and it's exacerbating the damaging ripple effect on working parents and their employers, according to global health company The Cigna Group (NYSE: CI). A new report by the Evernorth Research Institute details the increasing significance of the youth mental health crisis, the challenges parents face, and provides a roadmap of specific steps employers can take to better support today's workforce.
- PR Newswire
Evernorth announces Humira biosimilar available at $0 out of pocket for Accredo patients in June
In an important step toward driving long-term affordability and access to treatments for chronic and complex conditions, Evernorth Health Services announced that it will have a Humira® biosimilar available for $0 out of pocket for eligible patients of its specialty pharmacy Accredo beginning this June. The high- and low-concentration interchangeable biosimilar will be produced for Evernorth's affiliate private label pharmaceutical distributor, Quallent Pharmaceuticals, through agreements with mu
